Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 45,143

Document Document Title
WO/2018/126673A1
An application of albiflorin or a pharmaceutically acceptable salt thereof as an IDO inhibitor; albiflorin or a pharmaceutically acceptable salt thereof serving as an IDO inhibitor can be used for preparing a drug, food, health product, ...  
WO/2018/127830A1
The present invention relates to a composition which comprises peptides derived from S- Arrestin (retinal arrestin, S-antigen, S-Ag). The composition or peptides may be useful in the prevention and/or suppression of S-Ag autoimmunity, wh...  
WO/2018/126306A1
The present invention describes a pharmaceutical composition of biologically active peptides, associated with a controlled-release system using cyclodextrins or derivatives thereof, liposomes and biodegradable polymers and/or mixtures of...  
WO/2018/126522A1
An injectable intraocular sustained-release antiviral drug and a manufacturing method and application thereof. The antiviral drug is an insoluble phosphonoformate salt microcrystal. The insoluble phosphonoformate salt is a multivalent me...  
WO/2018/123918A1
Provided is a compound or a salt thereof, represented by the formula shown, which has a RORγt inhibitory effect and is useful as a preventive or therapeutic agent for autoimmune diseases, allergies, and the like.  
WO/2018/124107A1
The present invention provides a fusion protein of BDNF and an anti-human transferrin receptor antibody, wherein in a heavy-chain variable region of said antibody, (a) CDR1 includes an amino acid sequence of SEQ ID NO:66 or SEQ ID NO:67,...  
WO/2018/123968A1
In the present invention, mesenchymal stem cells cultured in a serum-free medium are used to provide a repair agent for repairing tissue damage in a living body and a method for producing said repair agent.  
WO/2018/123945A1
Provided are: a depot preparation comprising tafluprost which can form depots easily and can maintain the depot-formed state for a long period so that tafluprost can be sustainably released over a long period of time after in vivo admini...  
WO/2018/117014A1
An ophthalmic composition which comprises (A) one or more member selected from (A-1) vitamin A and (A-2) vitamin E and (B) nonionic surfactants and has a transmittance of 70% or higher, wherein the compositional mass ratio of the above i...  
WO/2018/113094A1
Disclosed is the use of a fullerene structure in the preparation of a drug for treating diabetes and complications thereof. The fullerene structure comprises at least one effective ingredient selected from the group consisting of an oil-...  
WO/2018/114557A1
The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of tacrolimus and a liquid vehicle comprising at least one semifluorinated alkane for use in a method of treating an intraocular ...  
WO/2018/112544A1
A biofilm disrupting composition for use on chronic wounds comprising (i) at least one biologically acceptable thiol based antioxidant(ii) at least one biofilm disruptor and (iii) at least one biocide. Also disclosed is a process of prep...  
WO/2018/119413A1
Products, compositions, and methods for using one or more small particles to facilitate the delivery of one or more antihistamines to a human body are disclosed. In some aspects, methods are disclosed that utilize small particles that ma...  
WO/2018/113758A1
Provided in the present application are a sulfonyl amidine as represented by formula (I) as an indoleamine-2,3-dioxygenase inhibitor, and a preparation method therefor and the use thereof. The compound of formula (I) in the present appli...  
WO/2018/112545A1
Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods ...  
WO/2018/117211A1
The present invention relates to an agent for treatment and/or prevention of eye diseases which contains 4-{[1R,2s,3S,5s,7s]-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[ 2,3-b]pyridine-5-carboxamide or a salt thereof.  
WO/2018/117244A1
Provided is a novel peptide that includes an amino acid sequence indicated by SEQ ID NO: 30, and inhibits protease activity.  
WO/2018/109484A1
The invention providesthecompound of formula (I): Said compound beinganinhibitor of Kv3 channels and of use in the prophylaxis or treatment of related disorders.  
WO/2018/109525A1
The present invention discloses new anti-angiogenic extracellular vesicles (extracellular vesicles, EV) formed from stem/stromal mesenchymal cells (also known as mesenchymal stem cells, MSC), said EVs for the treatment of diseases charac...  
WO/2018/107226A1
This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age- related macular degeneration, diabetic retinopathy, retinitis pigmen...  
WO/2018/107216A1
Disclosed herein are compounds according to Formula I; a pharmaceutical composition including, consisting essentially of, or consisting of: a pharmaceutically acceptable compound of Formula I and a pharmaceutically acceptable carrier, di...  
WO/2018/107201A1
The invention relates to functionalized dihydro— and tetrahydro-quinazoline compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as heparanase inhibitors for the treatment of diseases or condi...  
WO/2018/107984A1
The present invention discloses a polypeptide containing a T helper cell epitope (Th epitope), which can serve as an immunostimulant of a B cell epitope or a peptide hapten of a target antigen. The invention also discloses a polypeptide ...  
WO/2018/108969A1
The instant invention provides compounds of formula I which are selective JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as atopic dermatitis, arthritis, and cancer.  
WO/2018/109700A1
The present invention discloses new aiiti-angiogenic extracellular vesicles (extracellular vesicles, EV) formed from stent/stromal mesenchymal cells (also known as mesenchymal stem cells, MSC), said EVs for the treatment of diseases char...  
WO/2018/111156A1
The invention relates to the field of medicine and can be used in the pharmaceutical industry for producing a drug for treating a disease correlated with macular oedema associated with VEGF-A overexpression. An F(ab)2-fragment of anti-VE...  
WO/2018/108945A1
The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disord...  
WO/2018/107200A1
The invention relates to functionalized quinazoline compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as heparanase inhibitors for the treatment of diseases or conditions related to heparanse...  
WO/2018/105678A1
An ophthalmological composition which stabilizes the lacrimal lipid layer and contains liquid paraffin.  
WO/2018/107005A1
Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment t...  
WO/2018/102921A1
Herein presented are gold nanoparticles (AuNPs) used for the transport of medications to mucous membranes. The AuNPs are ultra-stable in that they withstand freeze-drying and heating treatments without noticeable change in their structur...  
WO/2018/105681A1
Provided is an ophthalmological composition which stabilizes the lacrimal lipid layer and has a clear external appearance. The ophthalmological composition contains (A) liquid paraffin and (B) a non-ionic surfactant, wherein the compound...  
WO/2018/105630A1
The present invention pertains to: a drug for preventing and/or treating cognitive dysfunction and/or a neurodegenerative disease accompanied by accumulation of prionoids, said drug comprising hemagglutinating virus of Japan envelope as ...  
WO/2018/106184A1
Disclosed is the use of heterocylic compounds of Formula (I) in the treatment of eye diseases, such as a retinal and/or choroid angiogenic disease selected from the group consisting of age-related macular degeneration (AMD), diabetic ret...  
WO/2018/102715A1
Cornea endothelium is the posterior cell monolayer of cornea that maintains corneal clarity via its pump function. This paper discloses that glutamine metabolism plays a crucial role in maintaining the energy supply for corneal endotheli...  
WO/2018/100178A1
The invention provides a method for the production of a zeolite particle composition which has optimized characteristics, such as enhanced adsorption and specific ion exchange properties. A method and an apparatus for producing improved ...  
WO/2018/100054A1
The present invention relates to methods and pharmaceutical compositions for the treatment of retinal degenerative diseases. The inventors identified a new key actor of the mechanism underlying the protective role of RdCVF: 6-phosphofruc...  
WO/2018/101434A1
The present invention addresses the problem of providing a glycosylated chlorin e6 derivative which has excellent tumor cell-killing properties (phototoxic property) and growth-inhibiting effect on tumor tissues and which is used for pho...  
WO/2018/095429A1
Disclosed is the use of a gold cluster or a gold cluster-containing substance in the preparation of a drug for preventing and/or treating glaucoma.  
WO/2018/097253A1
The purpose of the present invention is to provide a cell population suitable for transplanting retinal tissue, and a method for producing the cell population. The present invention provides: a cell population for transplantation, the ce...  
WO/2018/096196A1
The present invention relates to the therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration, inter alia.  
WO/2018/090112A1
The present invention relates to a method for obtaining nanostructured amphiphilic cationic lipid and amphiphilic cationic polymer compounds that can contain at least two pharmaceutical drugs, a hydrophobic and a hydrophilic drug, associ...  
WO/2018/094218A1
The instant invention provides methods and compositions related to discovery of c-fos as a therapeutic target for treatment or prevention of neuronal diseases or disorders that are characterized by angiogenesis, or of vascular diseases o...  
WO/2018/091859A1
The invention relates to pharmaceutical formulations comprising cyclodextrins that are topically applied to the external surface of the human eye, preferably as a liquid. The formulations have been shown to be capable of providing the cy...  
WO/2018/093797A1
The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.  
WO/2018/087092A1
This invention provides a method of lowering intraocular pressure in a patient having normal tension glaucoma, comprising contacting an eye of a subject having normal tension glaucoma with a pharmaceutical composition comprising an effec...  
WO/2018/089484A1
The present invention includes compositions and methods for the treatment, softening and removal of ear wax by administering to the ear a solution of a semi-fluorinated alkane according to the formula: RFRH or RFRHRF, wherein RF is a per...  
WO/2018/088566A1
Provided are a novel HIF inhibitor, and a therapeutic or prophylactic drug for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegeneration, or autoimmune disease, w...  
WO/2018/087677A1
The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: (I). Also provided are methods of making the compounds of Formula (I) and their methods of use.  
WO/2018/083326A1
The invention provides a hydrogen sulfide releasing polymer compound having a polysaccharide backbone, wherein the compound has at least two substructures, and wherein said substructures are capable of releasing hydrogen sulfide by thiol...  

Matches 1 - 50 out of 45,143